Core Insights - The article discusses the recent developments in the telehealth weight loss category, particularly focusing on Hims GLP-1 Weight Loss program and the introduction of a compounded semaglutide pill option [6][8][24] - There is a growing consumer interest in prescription weight loss treatments accessed through telehealth platforms, driven by the convenience and accessibility of online consultations with licensed healthcare providers [10][11] Group 1: Hims GLP-1 Weight Loss Program - Hims GLP-1 Weight Loss is a telehealth-based weight management program that connects consumers with licensed healthcare providers for evaluation and potential prescription of weight loss medications [23][24] - The program offers access to various treatment options, including FDA-approved GLP-1 medications like Wegovy and Zepbound, compounded GLP-1 medications, and oral medication kits [24][25] - Compounded medications, including semaglutide in both injectable and oral forms, are prepared by licensed pharmacies but are not FDA-approved, raising concerns about their safety and effectiveness [25][9] Group 2: Consumer Research and Telehealth Access - Increased public interest in telehealth weight loss treatments has led to more consumers researching their options, including understanding the differences between FDA-approved and compounded medications [4][8] - Telehealth platforms typically require a clinical evaluation by a licensed provider before issuing prescriptions, and not all services are available in every state due to varying regulations [12][22][29] - Pricing for the newly announced compounded semaglutide pill option starts at $49 for an introductory month, with variations based on plan and clinical determination [28] Group 3: Regulatory and Safety Considerations - The FDA has emphasized that compounded medications are not evaluated for safety, effectiveness, or quality, which is a critical distinction for consumers [17][9] - Off-label prescribing is common in medicine, allowing providers to prescribe FDA-approved medications for uses not specifically evaluated by the FDA [19] - Consumers are encouraged to consult qualified healthcare professionals for personalized guidance, especially those with complex medical histories or specific health conditions [35][36]

诺和诺德刚刚推出的减肥药片尚未站稳脚跟，就遭遇了一场意料之外的市场挑战。 2月5日周四，诺和诺德股价重挫，此前远程医疗公司Hims & Hers Health推出了诺和诺德减肥药Wegovy片剂的仿制版本， 定价仅为首月49美元，随后每月99美元，远低于诺和诺德的品牌药物149美元的起始月费。 诺和诺德本希望借助新品扭转颓势，但远程医疗公司推出的低价仿制版本迅速搅乱了市场格局，引发了关于药品专利保护 和监管框架的激烈交锋。 诺和诺德发表声明称，Hims此举属于"非法大规模复配，对患者构成重大风险"。公司表示，将采取法律和监管行动，以 保护患者、公司知识产权以及美国药品审批框架的完整性。 受此消息冲击，周四诺和诺德ADR股价跌超8%，竞争对手礼来公司也下跌7.1%。 远程医疗公司抢滩低价市场 Hims的仿制药片对诺和诺德的产品构成威胁。 据路透社报道，这款仿制品采用了"不同的配方和给药系统"，Hims发言人Abby Reisinger表示： 今天提供的复配司美格鲁肽片剂不是Wegovy的本质复制品。 尽管供应短缺已经结束，远程医疗公司本应停止销售仿制品，但它们通过调整剂量或添加成分，使产品被视为与品牌药物 足够 ...

-- Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks [Stocks Tumble for 3rd Straight Day][Is the Tech Stock Sell-Off 'Healthy'?][Bitcoin Continues Its Dramatic Decline] [The Job Market Freeze Has Deepened This Winter]- Top StoriesHims & Hers Health said its new weight-loss pill comes with same active ingredient as Novo Nordisk's Wegovy.Hims & HersClose### Key Takeaways- Shares of Eli Lilly and Novo Nordisk tumbled following the announcement, while Hims & Hers shares i ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill WegovyFILE - This photo shows Novo Nordisk headquarters in Bagsvaerd, Denmark, on Feb. 5, 2025. (Mads Claus Rasmussen/Ritzau Scanpix via AP, File)WASHINGTON -- Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill Wegovy, just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation of the blockbuster medication.The an ...

Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.The new Compounded Semaglutide Pill is formulated to protect the active ingredient during digestion and to support absorption.In 2025, Hims & Hers doubled its facility footprint to over one million square feet, integrating advanced pharmacy capabilities, lab testing, and R&D space.Hims & Hers said it adheres to all applicable federal ...

Hims Stock Slides After Launching Oral Wegovy Knockoff; Novo, Lilly Tumble | Investor's Business DailySPECIAL REPORT: [Find The Online Broker That Best Fits Your Needs]---Hims & Hers Health (HIMS) launched a compounded version of Novo Nordisk's (NVO) already popular weight-loss pill on Thursday. But Hims stock reversed its early gains, while Novo and Eli Lilly (LLY) continued falling. The compounded pill will cost just $49 for the first month, roughly $100 less than what Novo Nordisk is charging for its ora ...

Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan. ...

Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers He... ...

Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an i... ...

Core Insights - Eli Lilly reported Q4 earnings that exceeded analyst expectations, with a profit of $7.54 per share on sales of $19.3 billion, compared to forecasts of $6.93 per share on $17.9 billion in sales [1] - Despite strong earnings, Eli Lilly's stock fell 6% due to competitive pressures from Hims & Hers Health, which announced a new "needle-free" GLP-1 weight loss pill [1][3] Group 1: Eli Lilly's Performance - Eli Lilly's Q4 earnings beat expectations, forecasting full-year 2026 earnings between $33.50 and $35 per share [1] - The company achieved significant sales driven by injectable GLP-1 weight loss drugs Mounjaro and Zepbound in 2025 [2] Group 2: Competitive Landscape - Hims & Hers Health introduced a compounded semaglutide pill priced at $49 for the first month, which is significantly lower than Eli Lilly's Zepbound price of $299 for the lowest-dose formulation [3][4] - Hims & Hers plans to increase the price of its GLP-1 pill to $99 per month after the introductory period, but it remains competitive compared to Novo Nordisk's pricing [4][5] - Novo Nordisk offers its injectable Wegovy at $199 and its pill form at $149, indicating a competitive pricing environment for GLP-1 drugs [4]